¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×ܰæÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ gM;}#>6  
NCA {H^CL  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© VS?@y/\In  
vd#,DU=p!  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© ?3sT" r_d@  
BH0!6Oq  
1.Co-stimulators (or co-stimulating molecules) {gf>*  
aI#4H+/  
2.NK-kB Mj0Cat=  
^6/j_G  
3.Immunoglobulin superfamily j~ym<-[{a  
yYAnwf  
4.antigen-presenting cell (APC) zjbE 7^ N  
AvRcS]@=  
5.death domain 3_qdJ<,  
4E"d/  
6.CCR and CXCR {V2bU}5 [  
:B#EqeI  
7.Lectin (or mitogen) }X1.Wt=?  
2tr :xi@  
8.Clusters of differentiation, CD) LZWS^77  
!y vJpdsof  
9.B7 family q @Kk\m  
7u%a/<  
10.Cytotoxic T lymphocyte, CTL) ~"mj;5Id  
S!j^|!  
11.IL-15 and IL-15 receptor (IL-15R) 4: sl(r  
(L#%!bd  
12.MHC restriction 7Jx%JgF  
\RE c8nsLy  
13.Affinity-chromatography }K8Lm-.=  
{'IFWD.5  
14.Cyctosprin A, CsA npj/7nZj  
xYT}>#[  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) +Jw{qQR/*  
`` -k{C#F  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© aYj%w  
*]!l%Uf%  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 _<u;4RO(s  
6$z'wy/*  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ 0ny{)Sd6um  
G;2[  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ %]GV+!3S  
$nFAu}%C  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© ;Id"n7W  
V2QW\2@$  
ÃâÒßѧרҵ£º /hfUPO5  
>t,O2~  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ r]-+bR  
vrO%XvXW  
Ïû»¯ÄÚ¿Æ£º @SQceQfB  
Fv a] *5  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ 9F)W19i.  
/1N)d?Pcl  
ѪҺ²¡Ñ§×¨Òµ£º }JGq1  
K /ZHJkJ7  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
2+6=? ÕýÈ·´ð°¸:8
°´"Ctrl+Enter"Ö±½ÓÌá½»